High impact
Obinutuzumab (Gazyva®)
BCBS Tennessee·Effective Sep 30, 2026
This is a NEW medical policy (1 day old) for Obinutuzumab (Gazyva®) that establishes coverage criteria, prior authorization requirements, and documentation standards for multiple B-cell lymphomas, chronic lymphocytic leukemia, and lupus nephritis. The policy is APPROVED but NOT YET EFFECTIVE—do not implement until September 30, 2026. Billing teams must prepare systems now to enforce prior authorization requirements and specialty prescriber restrictions when the policy becomes active.